Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China

Version 1 : Received: 2 November 2023 / Approved: 3 November 2023 / Online: 3 November 2023 (11:12:59 CET)

A peer-reviewed article of this Preprint also exists.

Yang, Q.; Zou, Z.; Cao, W.; Shi, Y.; Xiao, X.; Chen, S.; Li, Y. Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China. COVID 2023, 3, 1707-1720. Yang, Q.; Zou, Z.; Cao, W.; Shi, Y.; Xiao, X.; Chen, S.; Li, Y. Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China. COVID 2023, 3, 1707-1720.

Abstract

Abstract: The COVID-19 pandemic significantly disrupted global healthcare systems. The impacts of SARS-CoV-2 infection on urticaria and its management are unknown. To collect information about patients with urticaria infected with SARS-CoV-2 and to investigate the impact of SARS-CoV-2 infection on urticaria severity, course, and treatment to better support recovery. This was a questionnaire-based study of patients with urticaria infected with SARS-CoV-2. Changes in urticaria severity (measured with the urticaria activity score (UAS)), course, and treatment were assessed before, during, and after SARS-CoV-2 infection. Mean (± SD) UAS scores were 5.17 ± 1.67, 4.23 ± 1.98, and 4.37 ± 1.93 before, during, and after SARS-CoV-2 infection, respectively (F = 8.839, p < 0.01). The median (IQR) wheal score was 0.464 (0.464, 0.763), 0.464 (0.138, 0.763), and 0.464 (0.138, 0.763) before, during, and after infection, respectively (Kruskal-Wallis H-test, H=12.230, p = 0.02). The median (IQR) pruritus score was 0.695 (0.395, 0.695), 0.394 (0.123, 0.695), and 0.394 (0.123, 0.695) before, during, and after infection, respectively (Kruskal-Wallis H-test, H = 21.001, p < 0.01). Within the limitations of a questionnaire study, urticaria appears to improve during SARS-CoV-2 infection, worsens slightly after recovery, and the frequency of Western medicine use increases.

Keywords

Urticaria; SARS-CoV-2 infection; COVID-19 pandemic; mast cells

Subject

Public Health and Healthcare, Public Health and Health Services

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.